DABIGATRAN – THE NEW APPROACH FOR DEEP VENOUS TROMBOSIS PROPHYLAXIS

T. B. Minasov; Минасов Т. Б.; B. Sh. Minasov; Минасов Б. Ш.; Sh. Z. Zagidullin; Загидуллин Ш. З.; N. Sh. Zagidullin; Загидуллин Н. Ш.; E. Caglayan; Каглаян Е.; N. Gassanov; Гассанов Н.

doi:10.21823/2311-2905-2011-0-3-80-83

DABIGATRAN – THE NEW APPROACH FOR DEEP VENOUS TROMBOSIS PROPHYLAXIS

Authors: Minasov T.B.¹, Minasov B.S.¹, Zagidullin S.Z.¹, Zagidullin N.S.¹, Caglayan E.², Gassanov N.²
Affiliations:
1. ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
2. Университетская клиника внутренних болезней, г. Кёльн
Issue: Vol 17, No 3 (2011)
Pages: 80-83
Section: Experience exchange
Submitted: 11.11.2016
Accepted: 11.11.2016
Published: 30.09.2011
URL: https://journal.rniito.org/jour/article/view/465
DOI: https://doi.org/10.21823/2311-2905-2011-0-3-80-83
ID: 465

Cite item

Full Text

Abstract

The amount of total joint replacement is more than 1.5 mln world wide and requirement is increasing each year. Nevertheless one of the most dramatic complication after orthopedic manipulations are deep venous trombosis. As known, two aspects of prophylaxis are most important: duration of treatment and the doses of drags. The aim of study was to analys the influence of dabigatran for the risk of postop complications with the short time patients treatment complains. Treatment combination with dabigatran was clinically effective and the rate of adversing events was low. Thus we can conclude that treatment complains of dabigatran significantly higher then traditional injections of low molecular weight heparins.

Keywords

joint replacement, deep venous trombosis, anticoagulants, dabigatran

профессор, заведующий кафедрой пропедевтики внутренних болезней

Россия

References

Blech, S. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans / S. Blech [et al.] // Drug. Metab. Dispos. – 2008. – Vol. 36. – P. 386–399.
Cohen, A.T. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study / A.T. Cohen [et al.] // Lancet. – 2008. – Vol. 371. – P. 387–394.
Connolly, S.J. Dabigatran versus warfarin in patients with atrial fibrillation / S.J. Connolly [et al.] // N. Engl. J. Med. – 2009. – Vol. 361. – P. 1139–1151.
Eriksson, B.I. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial / B.I. Eriksson [et al.] // J. Thromb. Haemost. – 2007. – Vol. 5. – P. 2178–2185.
Eriksson, B.I. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial / B.I. Eriksson [et al.] // Lancet. – 2007. – Vol. 370. – P. 949–956.
Hirsh, J. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range / J. Hirsh [et al.] // Chest. – 2001. – Vol. 119. – P. 8S–21S.
Liesenfeld, K.H. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis / K.H. Liesenfeld [et al.] // Br. J. Clin. Pharmacol. – 2006. – Vol. 62. – P. 527–537.
Hip fracture outcomes in people age fifty and over. Background paper, Office of Technology Assessment. Washington, DC: US GPO, 2004.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

DABIGATRAN – THE NEW APPROACH FOR DEEP VENOUS TROMBOSIS PROPHYLAXIS

Full Text

Abstract

Keywords

About the authors

T. B. Minasov

B. Sh. Minasov

Sh. Z. Zagidullin

N. Sh. Zagidullin

E. Caglayan

N. Gassanov

References

Supplementary files

This website uses cookies